Skip to main content

Breadcrumb

  1. Home

No risk adjustment or risk stratification

Asthma Emergency Department Visits

Percentage of patients with asthma who have greater than or equal to one visit to the emergency room for asthma during the measurement period.

CBE ID
1381

Asthma in Younger Adults Admission Rate (PQI 15)

Admissions for a principal diagnosis of asthma per 100,000 population, ages 18 to 39 years. Excludes admissions with an indication of cystic fibrosis or anomalies of the respiratory system, obstetric admissions, and transfers from other institutions.

CBE ID
0283

Asthma Medication Ratio

The percentage of patients 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

CBE ID
1800

Asthma: Pharmacologic Therapy for Persistent Asthma

Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication

Three rates are reported for this measure:
1. Patients prescribed inhaled corticosteroids (ICS) as their long term control medication
2. Patients prescribed other alternative long term control medications (non-ICS)
3. Total patients prescribed long-term control medication

CBE ID
0047

Atherosclerotic Disease - Lipid Panel Monitoring

The percentage of patients aged 12 years and older with coronary artery disease, or 18 years and older with cerebrovascular disease or peripheral vascular disease that have been screened for dyslipidemia with a lipid profile

CBE ID
0616e

Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy

Percentage of patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS2 risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism

CBE ID
1525